Vivian T. Yin, MD, MPH, FRCSC

Vivian T. Yin, MD, MPH, FRCSC

Oculoplastic & Orbital Surgeon

Clinical Expertise

Orbital and Ocular Adnexal Tumors; Complex Reconstruction of Eyelids or Orbit; Targeted Therapy for Eyelid and Orbit Cancer; Oculoplastic Surgery Including Eyelids and Lacrimal Surgery

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Accepted Insurance Providers

Dr. Yin accepts the following list of insurance providers. Select your insurance provider to see more details.

Contact and Location

Locations map

Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.

About Me

Education

MD, University of Toronto; MPH, Johns Hopkins Bloomberg School of Public Health

Residencies

Ophthalmology – University of Toronto

Fellowships

Ophthalmic Plastic & Reconstruction – MD Anderson Cancer Center

Board Certifications

Ophthalmology

I am a surgeon who specializes in treating tumors of the eye socket and surrounding tissue. I have expertise in reconstructing this area after cancer treatment. Whenever possible, I use minimally invasive techniques. This makes surgery easier for my patients and helps them continue to look and feel like themselves.

The possibility of losing an eye is often the most worrisome concern that people have when they come to see me. By using the latest research and innovations I can help my patients keep their eyes and optimize the function. Before surgery we’ll spend a lot of time together, discussing the nature of their disease and all of the possible treatment options. I want my patients to feel empowered to make the best decisions for their unique needs. I work closely with my expert colleagues across many departments to ensure that our patients receive coordinated, comprehensive care.

Outside of the operating room, I am an active researcher. I am studying the genetics of orbital tumors, with a focus on lacrimal gland tumors. My goal is to find mutations that we can target with treatments to help improve outcomes for people with these tumors.

Awards and Honors

  • Best Paper, American Academy of Ophthalmology Annual Meeting (2012)
  • Dr. Sigmund Vaile Award for Excellence in Surgery (2012)

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

Clinical Trials

Smiling doctors in the lab

Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Research and Publications

Esmaeli B, Yin VT, Hanna EY, Kies MS, William WN, Bell D, Frank SJ. Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma. Head Neck 2016;38(8):1258-62.

Yin VT, Esmaeli B. Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma. Curr Pharm Des 2017;23:655-659. PMID: 27928965

Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, Migden M, Thuro BA, Esmaeli B. Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol 2015 Apr 30 [Epub ahead of print] PMID:25935097

Yin VT, Warneke C, Merritt H, Esmaeli B. Number of excisions required to obtain clear surgical margins and prognostic value of AJCC T category for patients with eyelid melanoma. Br J Ophthalmol. 2014;98(12):1681-5. [Epub 2014 Jul 22]. PMID:25053759.

Tetzlaff M, Curry J, Yin V, Pattanaprichakul P, Manonukul J, Uiprasertkul M, Manyam G, Wani K, Aldape K, Zhang L, Prieto V, Esmaeli B. Distinct pathways in the pathogenesis of sebaceous carcinoma implicated by differentially express microRNAs. JAMA Ophthalmol. 2015; 133(10):1009-16. [Online First July 23, 2015.] doi:10.1001/jamaophthalmol.2015.2310

Yin VT, Wiraska TA, Esmaeli B. Cutaneous eyelid neoplasm as toxicity of vemurafenib therapy. Ophthal Plast Recontr Surg. 2015;31(4):e112-5. [Epub ahead of print, 2014 May 14]. PMID:24833447.